Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on August 31, 2007
Japanese Journal of Clinical Oncology 2007 37(9):658-672; doi:10.1093/jjco/hym086
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/9/658    most recent
hym086v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zytoon, A. A.
Right arrow Articles by El-Malah, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zytoon, A. A.
Right arrow Articles by El-Malah, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 Foundation for Promotion of Cancer Research

Recurrence-free Survival after Radiofrequency Ablation of Hepatocellular Carcinoma. A Registry Report of the Impact of Risk Factors on Outcome

Ashraf Anas Zytoon1,2,, Hiroshi Ishii3, Koji Murakami2, Mohamed Ramdan El-Kholy1, Junji Furuse3, Ahmed El-Dorry4 and Adel El-Malah5

1 Radiology Department, Menoufiya University School of Medicine, Menoufiya, Egypt
2 PET Center, Dokkyo University School of Medicine, Shimotsuga-gun, Tochigi, Japan
3 Hepatobiliary and Pancreatic Oncology Department, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
4 Interventional Radiology Department, Ain Shams University School of Medicine, Cairo, Egypt
5 Radiology Department, National Liver Institute, Menoufiya, Egypt

For reprints and all correspondence: Ashraf Anas Zytoon, Radiology Department, Faculty of Medicine, Menoufiya University, Shebin E1-Koom, Menoufiya, Egypt. E-mail: ashradio{at}yahoo.com

Received March 13, 2007; accepted April 25, 2007

Background: Despite the high complete necrosis rate of radiofrequency ablation (RFA), tumor recurrence, either local tumor recurrence or new tumor formation, remains a significant problem. Purpose of this study is to evaluate the pattern and risk factors for intrahepatic recurrence after percutaneous RFA for hepatocellular carcinoma (HCC).

Methods: We studied 40 patients with 48 HCCs (≤ 3.5 cm) who were treated with percutaneous RFA. The mean follow-up period was 24.1 ± 15.7 months. We evaluated the cumulative disease-free survival of overall intrahepatic recurrence, local tumor progression (LTP) and intrahepatic distant recurrence (IDR). Thirty host, tumoral and therapeutic risk factors were reviewed for significant tie-in correlation with recurrence: age; gender; whether RFA was the initial treatment for HCC or not; severity of liver disease; cause of liver cirrhosis; contact of tumor to major hepatic vessels and liver capsule; degree of approximation of tumor to the liver hilum; ablation time; degree of benign pre-ablational enhancement; sufficient safety margin; tumor multinodularity; tumor histological differentiation; tumor segmental location; maximum tumor diameter; degree of tumor pre-ablational enhancement at arterial phase CT, MRI or CT-angiography; and laboratory markers pre- and post-ablation (AFP, PIVKA II, TP, AST, ALT, ALP and TB).

Results: The incidence of overall recurrence, LTP and IDR was 65, 23 and 52.5%, respectively. The cumulative disease-free survival rates were 54.6, 74.8 and 78.3% at 1 year, 27.3, 71.9 and 46.3% at 2 years and 20, 71.9 and 29.4 at 3 years, respectively. Univariate and multivariate analysis showed that the significant risk factors for LTP were: tumor size ≥ 2.3 cm, insufficient safety margin, multinodular tumor, tumors located at segments 8 and 5, and patient's age > 65 years (P < 0.05). No significant risk factor relationship for IDR could be detected.

Conclusion: Our results would have clinical implications for advance warning and appropriate management of patients scheduled for RFA. Patients at risk of LTP should be closely monitored in the first year. Furthermore, regular long-term surveillance is essential for early detection and eradication of IDR.

Key Words: recurrence-free survival • risk ratio • RFA, radiofrequency ablation • HCC


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
Y. Park, Y.-s. Kim, H. Rhim, H. K. Lim, D. Choi, and W. J. Lee
Arterial Enhancement of Hepatocellular Carcinoma Before Radiofrequency Ablation as a Predictor of Postablation Local Tumor Progression
Am. J. Roentgenol., September 1, 2009; 193(3): 757 - 763.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
K. Mori, K. Fukuda, H. Asaoka, T. Ueda, A. Kunimatsu, Y. Okamoto, K. Nasu, K. Fukunaga, Y. Morishita, and M. Minami
Radiofrequency Ablation of the Liver: Determination of Ablative Margin at MR Imaging with Impaired Clearance of Ferucarbotran--Feasibility Study
Radiology, May 1, 2009; 251(2): 557 - 565.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.